Literature DB >> 32367812

[First case of COVID-19 treated with tocilizumab in Iceland].

Aron Hjalti Bjornsson1, Thorbjorg Olafsdottir2, Katrin Maria Thormar3, Mar Kristjansson4, Anna Sesselja Thorisdottir4, Bjorn Runar Ludviksson5, Sigurdur Guðmundsson6, Magnus Gottfredsson6.   

Abstract

A gentleman in his early fifties became ill with flu-like symptoms after vacationing abroad and was diagnosed with COVID-19 after returning to Iceland. A few days later he was admitted to the University Hospital, Landspitali, due to worsening respiratory symptoms and severe fatigue. A computed tomography scan of lthe lungs showed diffuse bilateral consolidations and ground glass changes. He developed respiratory failure and was transferred to the intensive care unit where he received further treatment, including tocilizumab (IL-6 receptor inhibitor). He subsequently showed clinical improvement and did not require endotracheal intubation.

Entities:  

Keywords:  COVID-19; Coronavirus; Cytokine storm; SARS-CoV-2; Tocilizumab

Mesh:

Substances:

Year:  2020        PMID: 32367812     DOI: 10.17992/lbl.2020.05.581

Source DB:  PubMed          Journal:  Laeknabladid        ISSN: 0023-7213            Impact factor:   0.548


  3 in total

Review 1.  Immunology, immunopathogenesis and immunotherapeutics of COVID-19; an overview.

Authors:  Leila Mohamed Khosroshahi; Mohsen Rokni; Tahmineh Mokhtari; Farshid Noorbakhsh
Journal:  Int Immunopharmacol       Date:  2021-01-05       Impact factor: 5.714

2.  The COVID-19 wave in Belgium during the Fall of 2020 and its association with higher education.

Authors:  Yessika Adelwin Natalia; Christel Faes; Thomas Neyens; Geert Molenberghs
Journal:  PLoS One       Date:  2022-02-25       Impact factor: 3.240

3.  Harnessing immunotherapy to combat COVID-19: A modern snake oil or silver bullet?

Authors:  Shivshankar Malkarjun Gunjegaonkar; Thukani Sathanantham Shanmugarajan; Mohanasundaram Arunsundar; Uppuluri Varuna Naga Venkata Arjun; Kadirrel Devi; Sagar Baliram Wankhede; Velayutham Ravichandiran
Journal:  Therapie       Date:  2020-11-01       Impact factor: 2.070

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.